These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38768617)

  • 1. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
    Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R; Diacon AH; Takuva S; Liu Y; Zheng B; Karwe V; Hafkin J
    Trials; 2024 Jan; 25(1):70. PubMed ID: 38243296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
    Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
    BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data.
    Mudde SE; Ayoun Alsoud R; van der Meijden A; Upton AM; Lotlikar MU; Simonsson USH; Bax HI; de Steenwinkel JEM
    J Infect Dis; 2022 Jun; 225(11):1876-1885. PubMed ID: 33606880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
    Dooley KE; Hendricks B; Gupte N; Barnes G; Narunsky K; Whitelaw C; Smit T; Ignatius EH; Friedman A; Dorman SE; Dawson R;
    Am J Respir Crit Care Med; 2023 Apr; 207(7):929-935. PubMed ID: 36455068
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Goodall RL; Meredith SK; Nunn AJ; Bayissa A; Bhatnagar AK; Bronson G; Chiang CY; Conradie F; Gurumurthy M; Kirenga B; Kiria N; Meressa D; Moodliar R; Narendran G; Ngubane N; Rassool M; Sanders K; Solanki R; Squire SB; Torrea G; Tsogt B; Tudor E; Van Deun A; Rusen ID;
    Lancet; 2022 Nov; 400(10366):1858-1868. PubMed ID: 36368336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial.
    Lee JK; Lee JY; Kim DK; Yoon HI; Jeong I; Heo EY; Park YS; Jo YS; Lee JH; Park SS; Park JS; Kim J; Lee SM; Joh JS; Lee CH; Lee J; Choi SM; Park JH; Lee SH; Cho YJ; Lee YJ; Kim SJ; Kwak N; Hwang YR; Kim H; Ki J; Lim JN; Choi HS; Lee M; Song T; Kim HS; Han J; Ahn H; Hahn S; Yim JJ
    Lancet Infect Dis; 2019 Jan; 19(1):46-55. PubMed ID: 30477961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.
    Manyazewal T; Woldeamanuel Y; Holland DP; Fekadu A; Blumberg HM; Marconi VC
    Trials; 2020 May; 21(1):383. PubMed ID: 32370774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.